[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reperfusion-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reperfusion-injury":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,80,119,149,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100620809","phase-2-prevention-of-reperfusion-injury-outcomes-through-effective-cardioprotection-targeting-myocardial-infarction-100620809",false,"NCT07362446","Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","A Randomised, Double-Blind, Placebo-Controlled, Study of Xolatryp in Patients Presenting With STEMI Undergoing Primary PCI","PROTECT-MI","Inclusion Criteria:\n\n* Have provided informed consent.\n* Male patients aged 40 to 75 years of age.- Female patients aged 55 to 75 years of age, or women aged 40 to 55 years that have no possibility of being pregnant.\n* Patient presents with first-time STEMI, scheduled to undergo primary PCI within 6 h of symptom onset and anticipated door to balloon time \\\u003C 2 h.\n* In combination with symptoms consistent with acute MI, patient must demonstrate ST-elevation at the J-point in two contiguous leads.\n* Hemodynamically stable including: systolic BP ≥ 90 mmHg, HR 50-120 bpm.\n* Killip Class I or II.\n* Oxygen saturation ≥ 92% on room air or low-flow oxygen.\n* No ongoing VT\u002FVF at enrolment.\n* Male participants with female partners of child-bearing potential must be ready and able to use highly effective methods of birth control for at least 7 days following IP administration.\n\nExclusion Criteria:\n\n* History or ECG evidence of myocardial infarction or cardiomyopathy.\n* Prior major cardiac surgery, including but not limited to coronary artery bypass graft surgery (CABG).\n* Known contraindication to CMR (e.g. pacemakers, cochlear implants, aneurism clips, claustrophobia, allergy to contrast medium).\n* History of clinically significant renal impairment requiring dialysis or an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin.\n* Estimated or known body weight \\\u003C 50 kg, \\> 120 kg at screening.\n* Concurrent enrolment in another investigational device or drug trial, or less than 30 days or 5 half-lives of investigational device or drug (whichever is longer), since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Patients who are participating in non-interventional, purely observational trials can be included.\n* Life expectancy of less than 1 year due to non-cardiac pathology in the opinion of the Investigator.\n* Any condition or significant clinical abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study.\n* Known history of hypersensitivity to the investigational drug, or excipients, or do not want to be exposed to soy or egg (including products and derivatives).","ALL","40 Years","75 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will be tested in this study.\n\nParticipants are put into two groups randomly, which means by chance. One group receives a single 6-hour continuous intravenous infusion of Xolatryp and one group receives placebo. Participants are in the study for about 30 days.\n\nPlacebo infusion looks like Xolatryp but do not contain any medicine. Participants are followed up via telephone and there is one visit to the study site on day 30.\n\nHeart health is assessed based on the analysis of blood samples, which are collected at the study site, via electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance (CMR) imaging. At the end of the study, the results are compared between the two groups. During the study, the doctors also regularly check the general health of the participants.",[28,29,30,31],"Myocardial Infarction","Reperfusion Injury","AMI","STEMI (ST Elevation MI)",[33,34],"STEMI","PCI","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2026-04-22",{"date":43,"type":22},"2027-09-30",{"name":45,"class":46},"Nyrada Pty Ltd","INDUSTRY",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100635765","light-utilization-cox-inhibitory-device-therapy-for-infant-cardiac-arrest-lutica-study-the-lucid-device-is-used-in-the-treatment-of-ischemic-brain-reperfusion-injury-caused-by-cardiac-arrest-in-pediatric-patients-100635765","NCT07556939","Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.","Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study)","LUTICA","Inclusion Criteria\n\nSubjects must meet ALL of the following criteria to be eligible for participation in the study:\n\n* In advance of the IHCA, a consent form signed by the Legally Authorized Representative (LAR) such as a parent\u002Fguardian will be attained.\n* Age greater than 48 hours and less than 1 year (with a corrected gestational age of at least 38 weeks).\n* Greater than or equal to 2.5 kg body weight.\n* Acquired or congenital heart disease.\n* Society of Thoracic Surgeons- European Association for Cardio-Thoracic Surgery (STAT) categories 4 and 5\" and those patients with medical cardiac conditions with an admission diagnosis of acute heart failure, if blood lactate levels are greater than 3 mmol\u002FL, or if mechanically ventilated within 4 hours of admission.\n* Chest compressions for at least 2 minutes (120 seconds) during IHCA with ROC; Modified Glasgow Coma Scale for Infants and Children will be used to determine eligibility.\n* Coma or encephalopathy after ROC. Coma or encephalopathy after ROC, Modified Glasgow Coma Scale for Infants and Children will be used to determine eligibility.\n* Requires mechanical ventilation (i.e., via endotracheal tube or tracheostomy).\n* The cardiac arrest was unplanned (i.e., not part of cardiac surgical procedure).\n* A patient with a condition in which direct contact with the scalp is contraindicated such as decubitus ulcers, cellulitis, cuts, nicks, scratches, or other conditions with disrupted scalp integrity, will not be eligible for treatment, but will be eligible for the study and data collected will be used as control data.\n\nExclusion Criteria:\n\nSubjects must be EXCLUDED from participation in this study if ANY of the following criteria are met:\n\n* The Legally Authorized Representative does not speak English or Spanish\n* The LUCID cap is impossible to place within two (2) hours of ROC.\n* Preterm neonates (with a corrected gestational age of less than 38 weeks) due to the potential incompatibility with cap sizes, lack of information on depth of targeted brain structures, potential for waveguide overlap, and increased skin frailty.\n* Patients with a head size outside of the range of cap requirements: 32-49cm.\n* Modified Glasgow Coma Scale for Infants and Children motor response of six (infants, normal spontaneous movement) prior to treatment.\n* Duration of chest compressions greater than 60 minutes inclusive of ECMO deployment.\n* Pre-existing severe neurodevelopmental deficits with PCPC = 5 or progressive degenerative encephalopathy.\n* Central nervous system tumor with ongoing chemotherapy or radiation therapy.\n* Pre-existing terminal illness with life expectancy \\\u003C 3 months.\n* Progressive degenerative encephalopathy.\n* Cardiac arrest was associated with severe brain, thoracic, or abdominal trauma\n* Active and refractory severe bleeding prior to treatment.\n* Continuous infusion of epinephrine or norepinephrine at very high doses (≥ 2 μg\u002Fkg\u002Fminute).\n* Patient is newborn with acute birth asphyxia.\n* Patient cared for in a neonatal intensive care unit (NICU) after arrest (i.e., would not be admitted to PICU).\n* Patient has sickle cell anemia.\n* Patient known to have pre-existing cryoglobulinemia.\n* Patient known to have progressive degenerative encephalopathy.\n* Patient is known to have neurological issues including convulsions\u002Fepileptic seizures, intraventricular hemorrhage, Hypoxic-ischemic encephalopathy, periventricular leukomalacia, and retinopathy of prematurity.\n* Patient is known to have a recorded temperature at treatment\u002FLDU site out of range.\n* Lack of commitment to aggressive intensive care therapies including do not resuscitate orders and other limitations to care.\n* History of a prior cardiac arrest with chest compressions for at least two minutes during the current hospitalization but outside the 2-hour window for treatment.\n* Patient cared for in a neonatal intensive care unit (NICU) after arrest (i.e., not admitted to pediatric ICU (PICU)\u002FCICU).\n* Patients with prior or concurrent enrollment in any other neurotherapeutic trial, which may confound this study's results and expose patients to the unknown risks of multiple investigational treatments.\n* Patient participation in a concurrent interventional trial whose protocol, in the judgment of the LUCID investigators, prevents effective application of LUCID, or otherwise significantly interferes with carrying out the LUCID protocol. We will use the Neonatal Adverse Event Severity Scale.\n* Previous enrollment in or termination from LUTICA trial.","48 Hours","1 Year",{"count":59,"type":22},30,[61],"NA","Approximately 15,200 children receive cardiopulmonary resuscitation (CPR) for in-hospital cardiac arrest (IHCA) each year in the United States. Of these, about 60% are less than one year of age. Most IHCA (85-90%) occurs in intensive care units (ICU) or other monitored settings. Risk of IHCA is higher among children with cardiac disease compared to children with other diagnoses. A report based on the Pediatric Cardiac Critical Care Consortium (PC4) registry found 3.1% of children hospitalized in pediatric cardiac ICUs had a cardiac arrest; rates varied from 1% to 5.5 % across sites. Survival to hospital discharge after CA in children included in the PC4 registry was 53%, and lower for medical cardiac patients (37.7%) than for surgical cardiac patients (62.5%). Among survivors of pediatric IHCA, neurologic morbidities are common including cognitive, motor, and adaptive functional deficits. Despite high mortality and morbidity, treatment for children after IHCA is mainly supportive. Preventing fever and hypotension, maintaining normoxia, and treating seizures are emphasized. Ischemia-reperfusion injury to the brain is a primary cause of neurologic morbidity after IHCA. Ischemia-reperfusion leads to increased production of cytotoxic mitochondrial reactive oxygen species (ROS). Recently, specific wavelengths of near infrared light (NIR) (750 nm and 950 nm) have been discovered to partially inhibit cytochrome c oxidase activity (COX), reversibly reducing mitochondrial respiration and generation of ROS. Light Utilization COX Inhibitory Device (LUCID) is a novel medical device intended to safely deliver therapeutic NIR to the infant brain to prevent reperfusion injury. This protocol describes the \"LUCID Therapy for Infant Cardiac Arrest\" (LUTICA) clinical trial. LUTICA will investigate the safety, feasibility, acceptability, and probable benefit of the LUCID device in infants with acquired or congenital cardiac disease who experience unplanned IHCA. The hypothesis of the LUTICA trial is that application of the LUCID light box and cap immediately following IHCA in infants with acquired or congenital heart disease will be safe, feasible, and acceptable in the ICU setting, and demonstrate probable benefit toward favorable neurological outcomes.",[29,64],"Post Cardiac Arrest Brain Injury",[66,67,68,69],"infrared light therapy","mitochondrial therapy","photobiomodulation therapy","pediatric brain injury","NOT_YET_RECRUITING",{"date":72,"type":39},"2026-04-29",{"date":74,"type":22},"2026-07-15",{"date":76,"type":22},"2030-07-15",{"name":78,"class":46},"Mitovation, Inc",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":102,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":79},"100633435","head-cooling-in-ischaemic-stroke-patients-undergoing-endovascular-thrombectomy-coolhead-2b-100633435","NCT07526649","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","COOLHEAD-2B","Inclusion Criteria:\n\n* Acute anterior circulation ischaemic stroke planned for endovascular thrombectomy\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score \\>2\n* Core body temperature \\\u003C35°C at admission\n* Uncontrolled hypertension (≥185\u002F110 mmHg despite treatment in IVT-eligible patients)\n* Known contraindications to hypothermia (e.g., haemodynamic instability, symptomatic bradyarrhythmia, cryoglobulinaemia, sickle cell disease, cold agglutinins)\n* Vasospastic disorders (e.g., Raynaud's phenomenon)\n* Skin lesions preventing secure application of the cooling cap\n* Inability to participate in 90-day follow-up","18 Years",{"count":90,"type":22},182,[61],"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.",[94,95,96,97,98,99,29,100,101],"Stroke","Acute Ischemic Stroke","Brain Ischemia","Ischaemic Stroke","Thrombectomy","Endovascular Procedures","Cooling","Large Vessel Occlusion",[103,104,105,106,107,108],"Head cooling","Selective brain cooling","Endovascular thrombectomy","Therapeutic hypothermia","Penumbra","Neuroprotection","2026-04-09",{"date":111,"type":39},"2026-04-13",{"date":113,"type":22},"2026-04-10",{"date":115,"type":22},"2029-06-30",{"name":117,"class":118},"Auckland City Hospital","OTHER_GOV",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":79},"100559677","intracoronary-hypothermia-as-a-prevention-of-reperfusion-injury-in-myocardial-infarction-100559677","NCT06567249","Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.","Selective Intracoronary Hypothermia as a Prevention of Reperfusion Injury in ST-elevation Myocardial Infarction.","Inclusion Criteria:\n\n* Acute ST-elevation myocardial infarction\n* Time from onset of symptoms less than 12 hours\n* Given informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Cardiogenic shock\n* Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block.\n* Sick sinus syndrome requiring implantable pacemaker\n* Pulmonary edema\n* Active inflammatory condition\n* Active chemo\u002Fradiation therapy","90 Years",{"count":128,"type":22},60,[61],"Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.",[28,132,29,133],"ST-Elevation Myocardial Infarction (STEMI)","Microvascular Occlusion",[135,136,137,138,33],"hypothermia","ST-elevation myocardial infarction","microvascular obstruction","reperfusion injury","2025-12-08",{"date":141,"type":39},"2025-12-16",{"date":143,"type":39},"2024-05-05",{"date":145,"type":22},"2026-12",{"name":147,"class":148},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100602586","effect-inhaled-nitric-oxide-in-adult-liver-transplant-100602586","NCT07125443","Effect Inhaled Nitric Oxide in Adult Liver Transplant","Effect of Intraoperative Inhaled Nitric Oxide on Reperfusion Syndrome and Vasoplegia in Adult Liver Transplant Recipients: A Prospective Before-After Study","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Undergoing or underwent (for the retrospective \"before\" group) primary orthotopic liver transplantation. Retrospective data collection for retrospective group will take place between January 1, 2020 - May 31, 2025.\n* Written informed consent obtained for patients in the prospective (\"after\") group\n\nExclusion Criteria:\n\n* History of pulmonary arterial hypertension (mean pulmonary artery pressure ≥ 25 mmHg)\n* Re-transplantation\n* Acute fulminant hepatitis\n* Combined organ transplantation (e.g., liver-kidney)\n* Lack of complete data for propensity matching - Inability to communicate in the English language",{"count":157,"type":22},260,[61],"Liver transplantation remains the only cure for patients with end-stage liver disease. Despite continuous advances in medical care, ischemia-reperfusion injury (IRI) (tissue damage that occurs when blood supply is restored to an area that has been deprived of oxygen) remains a major contributor to complications with the newly transplanted liver. IRI can lead to a condition known as post-reperfusion syndrome that involves profound narrowing of blood vessels, significantly low blood pressure, and an increased requirement of medication to control blood pressure. In some cases, post-reperfusion syndrome can progress to a condition known as post-reperfusion vasoplegia which is a condition where severely low blood pressure persists even after blood flow is restored to the liver. This is often accompanied by complications such as improperly functioning kidneys, blood clotting disorders, and complications with the transplanted liver that can significantly affect patient outcomes. Recent studies have shown than inhaled nitric oxide (a gas that can relax blood vessels) can reduce the severity of IRI in the liver. This study is being conducted to determine whether the administration of inhaled nitric oxide during surgery reduces the severity of post-reperfusion syndrome and the incidence of post-reperfusion vasoplegia in adult patients undergoing liver transplantation. This is a before-and-after study design that will involve both the retrospective collection of data between the time period of January 1, 2020 - May 31, 2025 and prospective interventions involving adult liver transplant recipients.",[161,29,162],"Liver Diseases","Vasoplegia",[164,165],"Inhaled Nitric Oxide","Anesthesia","2025-08-14",{"date":168,"type":39},"2025-08-15",{"date":170,"type":22},"2025-09-01",{"date":172,"type":22},"2027-01-01",{"name":174,"class":148},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100483381","phase-1-hydrogens-feasibility-and-safety-as-a-therapy-in-ecpr-100483381","NCT05574296","Hydrogen's Feasibility and Safety as a Therapy in ECPR","Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation","HydrogenFAST","INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Patients admitted to a cardiac intensive care unit at a participating site with cardiac comorbidity, including congenital heart disease, myocarditis, cardiac arrhythmia, or rejection of a transplanted heart.\n2. Patients are anticipated to be between birth to 18 years of age, although occasionally a patient over the age of 18 may be enrolled.\n3. Patient experiencing a refractory cardiac arrest \\>5 minutes and receiving ongoing CPR in the ICU, cardiac catheterization lab, or cardiac operating room.\n4. The decision made by the clinical team to resuscitate from ongoing, refractory cardiac arrest using ECPR due to a lack of other available options.\n\nEXCLUSION CRITERIA\n\nMeeting any of the following criterion renders the patient ineligible for the trial:\n\n1. Enrollment in the opt-out program.\n2. Patients known to be pregnant.\n3. Patients who are prisoners.\n4. Prior ECPR episode during admission (whether or not they were enrolled in the trial).\n5. Enrollment does not occur within 6 hours of the decision to resuscitate using ECPR.\n\nNote that ECMO cannulation without preceding CPR does not qualify as ECPR and such patients will not be included.",{"count":184,"type":22},53,[186],"PHASE1","The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.",[189,190,29],"Cardiac Arrest","Extracorporeal Membrane Oxygenation","2025-07-01",{"date":193,"type":39},"2025-07-03",{"date":195,"type":39},"2024-03-04",{"date":197,"type":22},"2027-08-31",{"name":199,"class":148},"Boston Children's Hospital",4]